Pharmacodynamic studies of beta adrenergic antagonism induced in man by propranolol and practolol

The Journal of Clinical Investigation
G BodemC A Chidsey

Abstract

The pharmacodynamic activities of two beta adrenergic antagonists, propranolol and practolol, were compared in eight hypertensive patients. The activity of each antagonist was established in relation to its blood concentration at maximal and submaximal adrenergic blockade defined by inhibition of exercise tachycardia. Maximal inhibition of exercise tachycardia was comparable with both drugs and averaged 74+/-7% of the control value during drug treatment. This inhibition was achieved with a blood concentration of 2.5+/-0.4 mug/ml practolol and 0.10+/-0.08 mug/ml propranolol. The antagonist activities of these drugs against adrenergic stimulation with isoproterenol infusion indicated a much greater relative potency of propranolol against this stimulus, and in vivo estimates of PA(2) values differed by more than 600-fold. Relative antagonist activity of practolol during isoproterenol stimulation was equivalent both at cardiac (inotropic and chronotropic) and at vascular adrenergic receptors, whereas greater antagonist activity of propranolol was observed at vascular receptors than at cardiac receptors. Thus, the activity of practolol was not limited to cardiac receptors as previously suggested. Practolol did not reduce cardiac out...Continue Reading

References

Feb 10, 1967·Annals of the New York Academy of Sciences·J R Blinks
Jan 1, 1968·British Journal of Pharmacology and Chemotherapy·D Dunlop, R G Shanks
Sep 1, 1969·The Journal of Clinical Endocrinology and Metabolism·N WinerA D Freedman
Mar 5, 1970·The New England Journal of Medicine·E GilmoreC A Chidsey
Sep 26, 1970·British Medical Journal·D J Coltart, D G Shand
Jan 1, 1972·Circulation·D F LeonR H McDonald
Mar 1, 1968·Circulation·E D FrohlichI H Page
Jan 4, 1969·British Medical Journal·B N Prichard, P M Gillam
Apr 1, 1969·The American Journal of Cardiology·A M WeisslerC D Schoenfeld
Nov 1, 1965·The Journal of Clinical Investigation·S EpsteinE Braunwald
Sep 27, 1962·The New England Journal of Medicine·C A ChidseyE BRAUNWALD

Citations

Jan 1, 1981·European Journal of Applied Physiology and Occupational Physiology·U Boutellier, E A Koller
Jul 26, 1974·European Journal of Clinical Pharmacology·C R Kumana, C M Kaye
Jul 19, 1977·European Journal of Clinical Pharmacology·E Q RolandP M Milliez
Nov 14, 1977·European Journal of Clinical Pharmacology·J SassardP Zech
Mar 26, 1979·European Journal of Clinical Pharmacology·V M OhP Turner
Dec 19, 1975·European Journal of Clinical Pharmacology·G G GeyskesE J Mees
Jan 1, 1974·European Journal of Clinical Pharmacology·R GuglerH J Dengler
Jan 1, 1975·European Journal of Clinical Pharmacology·L BrunnerD Jack
Dec 18, 1978·European Journal of Clinical Pharmacology·O F ElseI R Edwards
Oct 31, 1975·The American Journal of Cardiology·J M Wallace
Nov 1, 1975·European Journal of Pharmacology·B N SinghR M Whitlock
Feb 24, 1998·The Journal of Emergency Medicine·J N Love
Jan 1, 1975·Clinical and Experimental Pharmacology & Physiology·J F GreenR Zelis
Nov 1, 1978·Clinical and Experimental Pharmacology & Physiology·J D Fitzgerald, S R O'Donnell
Nov 23, 1974·British Medical Journal·C R KumanaD M Smith
Sep 1, 1975·The Journal of Clinical Investigation·J J LertoraF M ABBOUD
Aug 1, 1978·British Journal of Clinical Pharmacology·V M OhJ Wadsworth
Sep 30, 1976·European Journal of Clinical Pharmacology·J F De PlaenT Reybrouck
Jul 26, 1974·European Journal of Clinical Pharmacology·G BodemR Gugler
Mar 22, 1976·European Journal of Clinical Pharmacology·H C BrownR G Shanks
Mar 17, 1978·European Journal of Clinical Pharmacology·R Gugler, G Bodem
Mar 1, 1978·British Journal of Clinical Pharmacology·L G DringR L Smith
Feb 1, 1977·British Journal of Clinical Pharmacology·J M BellD G McDevitt
Aug 1, 1975·British Journal of Clinical Pharmacology·C M CastledenR L Parsons
Dec 1, 1976·British Journal of Clinical Pharmacology·S G CarruthersD G McDevitt
Jan 1, 1979·British Journal of Clinical Pharmacology·A S Ling, J T Groel
Jan 1, 1985·Clinical and Experimental Hypertension. Part A, Theory and Practice·M A van BaakJ F Smits
Jul 19, 1975·Lancet·C R KumanaJ Hamer
Apr 1, 1985·Journal of Clinical Pharmacology·L D DeLeveF H Leenen
Jul 1, 1975·Circulation·A S Nies, D G Shand
Apr 1, 1982·Circulation·D L SableL D Horwitz
May 1, 1988·Clinical Cardiology·M W WestonG H Lyman
Jan 1, 1976·Acta Medica Scandinavica·J Schaanning, J S Vilsvik
Jun 16, 1999·Journal of Applied Physiology·C ClarP A Robbins
Oct 1, 1980·British Journal of Clinical Pharmacology·R GuglerG Bodem

Related Concepts

Acetanilides
Adrenergic beta-Antagonists
Amino Alcohols
Diastolic Blood Pressure
Cardiac Output
Dose-Response Relationship, Drug
Pulse Rate
Novodrin
Rexigen
Propylamines

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Lipidomics & Rhinovirus Infection

Lipidomics can be used to examine the lipid species involved with pathogenic conditions, such as viral associated inflammation. Discovered the latest research on Lipidomics & Rhinovirus Infection.

Alzheimer's Disease: MS4A

Variants within the membrane-spanning 4-domains subfamily A (MS4A) gene cluster have recently been implicated in Alzheimer's disease in genome-wide association studies. Here is the latest research on Alzheimer's disease and MS4A.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Torsion Dystonia

Torsion dystonia is a movement disorder characterized by loss of control of voluntary movements appearing as sustained muscle contractions and/or abnormal postures. Here is the latest research.

Generating Insulin-Secreting Cells

Reprogramming cells or using induced pluripotent stem cells to generate insulin-secreting cells has significant therapeutic implications for diabetics. Here is the latest research on generation of insulin-secreting cells.

Central Pontine Myelinolysis

Central Pontine Myelinolysis is a neurologic disorder caused most frequently by rapid correction of hyponatremia and is characterized by demyelination that affects the central portion of the base of the pons. Here is the latest research on this disease.

Epigenome Editing

Epigenome editing is the directed modification of epigenetic marks on chromatin at specified loci. This tool has many applications in research as well as in the clinic. Find the latest research on epigenome editing here.